Insider Buying: Solventum (NYSE:SOLV) Director Buys 1,475 Shares of Stock

Key Points

• Director Amy Mcbride Wendell bought 1,475 shares at an average price of $68.03 ($100,344 total), increasing her holdings to 5,039 shares — a 41.39% boost to her position.
• Solventum beat quarterly EPS estimates ($1.57 vs. $1.50) on $2.0B in revenue and set FY2026 guidance of $6.40–$6.60 EPS, roughly in line with analysts' ~6.58 estimate.
• The board authorized a $1.0 billion buyback (up to 7.5% of shares); the stock has a market cap of $11.72B, a P/E of 7.62, a 12‑month range of $60.70–$88.20, and a consensus price target of $93.70 (Moderate Buy).

Solventum Corporation (NYSE:SOLV - Get Free Report) Director Amy Mcbride Wendell purchased 1,475 shares of Solventum stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the acquisition, the director owned 5,039 shares of the company's stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Solventum Stock Performance

SOLV stock opened at $67.57 on Wednesday. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $88.20. The firm has a market cap of $11.72 billion, a price-to-earnings ratio of 7.62, a PEG ratio of 1.12 and a beta of 0.40. The business's fifty day simple moving average is $77.14 and its two-hundred day simple moving average is $76.13. The company has a quick ratio of 0.89, a current ratio of 1.23 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. During the same quarter in the previous year, the business earned $1.41 earnings per share. Solventum's quarterly revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum announced that its Board of Directors has authorized a stock buyback program on Thursday, November 20th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to purchase up to 7.5% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's management believes its shares are undervalued.

Hedge Funds Weigh In On Solventum

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Solventum by 5.3% in the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company's stock valued at $1,249,847,000 after purchasing an additional 867,837 shares during the period. Independent Franchise Partners LLP lifted its holdings in shares of Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company's stock worth $1,216,785,000 after purchasing an additional 2,456,451 shares during the period. State Street Corp boosted its position in Solventum by 2.0% in the fourth quarter. State Street Corp now owns 6,344,761 shares of the company's stock valued at $502,759,000 after buying an additional 124,490 shares during the last quarter. Davis Selected Advisers increased its holdings in Solventum by 12.7% in the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company's stock worth $492,880,000 after buying an additional 702,461 shares during the period. Finally, Boston Partners raised its position in Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company's stock worth $338,006,000 after buying an additional 959,543 shares during the last quarter.

Wall Street Analyst Weigh In

SOLV has been the subject of a number of research reports. Mizuho set a $100.00 price objective on shares of Solventum and gave the stock an "outperform" rating in a research note on Tuesday, January 20th. Weiss Ratings restated a "hold (c)" rating on shares of Solventum in a report on Tuesday, January 27th. BTIG Research reiterated a "buy" rating and set a $100.00 price objective on shares of Solventum in a research note on Friday, February 27th. Stifel Nicolaus lifted their price objective on shares of Solventum from $88.00 to $105.00 and gave the company a "buy" rating in a report on Wednesday, January 7th. Finally, UBS Group restated a "neutral" rating on shares of Solventum in a report on Friday, November 21st. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $93.70.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.